Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 6 |
| 1.1 List of Tables | 5 | 2 |
| 1.2 List of Figures | 7 | 2 |
| 2 Global Contraceptives Market: Introduction | 9 | 1 |
| 2.1 GBI Research Report Guidance | 9 | 1 |
| 3 Global Contraceptives Market: Market Overview | 10 | 2 |
| 3.1 Introduction | 10 | 1 |
| 3.1.1 Drivers and Barriers | 11 | 1 |
| 3.1.1.1 Drivers for the Contraceptives Market | 11 | 1 |
| 3.1.1.2 Barriers for the Contraceptives Market | 11 | 1 |
| 3.1.2 Opportunity and Unmet Need | 11 | 1 |
| 4 Global Contraceptives Market: Market Characterization | 12 | 8 |
| 4.1 Revenue | 12 | 1 |
| 4.2 Annual Cost of Treatment | 13 | 1 |
| 4.3 Treatment Usage Patterns | 14 | 2 |
| 4.3.1 Target Population | 16 | 1 |
| 4.3.2 Treatment Seeking Population | 17 | 1 |
| 4.3.3 Population Taking Prescribed Contraceptive Drugs | 18 | 1 |
| 4.3.4 Population Taking OTC Contraceptive Drugs | 19 | 1 |
| 5 Global Contraceptives Market: Geographical Landscape | 20 | 25 |
| 5.1 Revenue Analysis by Geography | 20 | 1 |
| 5.2 The US | 20 | 1 |
| 5.2.1 Revenue | 20 | 2 |
| 5.2.2 Annual Cost of Treatment | 22 | 1 |
| 5.2.3 Treatment Usage Patterns | 23 | 2 |
| 5.2.3.1 Target Population | 25 | 1 |
| 5.2.3.2 Treatment Seeking Population | 26 | 1 |
| 5.2.3.3 Population Taking Prescribed Contraceptive Drugs | 27 | 1 |
| 5.2.3.4 Population Taking OTC Contraceptive Drugs | 28 | 1 |
| 5.3 Top Five Countries of Europe | 29 | 1 |
| 5.3.1 Revenue | 29 | 1 |
| 5.3.2 Annual Cost of Treatment | 30 | 1 |
| 5.3.3 Treatment Usage Patterns | 31 | 2 |
| 5.3.3.1 Target Population | 33 | 1 |
| 5.3.3.2 Treatment Seeking Population | 34 | 1 |
| 5.3.3.3 Population Taking Prescribed Contraceptive Drugs | 35 | 1 |
| 5.3.3.4 Population Taking OTC Contraceptive Drugs | 36 | 1 |
| 5.4 Japan | 37 | 1 |
| 5.4.1 Revenue | 37 | 1 |
| 5.4.2 Annual Cost of Treatment | 38 | 1 |
| 5.4.3 Treatment Usage Patterns | 39 | 2 |
| 5.4.3.1 Target Population | 41 | 1 |
| 5.4.3.2 Treatment Seeking Population | 42 | 1 |
| 5.4.3.3 Population Taking Prescribed Contraceptive Drugs | 43 | 1 |
| 5.4.3.4 Population Taking OTC Contraceptive Drugs | 44 | 1 |
| 6 Global Contraceptives Market: Therapeutic Landscape | 45 | 24 |
| 6.1 Oral Contraceptives Market | 45 | 1 |
| 6.1.1 Revenue | 45 | 1 |
| 6.1.2 Annual Cost of Treatment | 46 | 1 |
| 6.1.3 Treatment Usage Patterns | 47 | 2 |
| 6.1.3.1 Target Population | 49 | 1 |
| 6.1.3.2 Treatment Seeking Population | 50 | 1 |
| 6.1.3.3 Population Taking Prescribed Contraceptive Drugs | 51 | 1 |
| 6.1.3.4 Population Taking OTC Contraceptive Drugs | 52 | 1 |
| 6.2 Injectables Market | 53 | 1 |
| 6.2.1 Revenue | 53 | 1 |
| 6.2.2 Annual Cost of Treatment | 54 | 1 |
| 6.2.3 Treatment Usage Patterns | 55 | 2 |
| 6.2.3.1 Target Population | 57 | 1 |
| 6.2.3.2 Treatment Seeking Population | 58 | 1 |
| 6.2.3.3 Population Taking Prescribed Contraceptive Drugs | 59 | 1 |
| 6.2.3.4 Population Taking OTC Contraceptive Drugs | 60 | 1 |
| 6.3 Topical Contraceptives Market | 61 | 1 |
| 6.3.1 Revenue | 61 | 1 |
| 6.3.2 Annual Cost of Treatment | 62 | 1 |
| 6.3.3 Treatment Usage Patterns | 63 | 2 |
| 6.3.3.1 Target Population | 65 | 1 |
| 6.3.3.2 Treatment Seeking Population | 66 | 1 |
| 6.3.3.3 Population Taking Prescribed Contraceptive Drugs | 67 | 1 |
| 6.3.3.4 Population Taking OTC Contraceptive Drugs | 68 | 1 |
| 7 Global Contraceptives Market: Pipeline Analysis | 69 | 5 |
| 7.1 Introduction | 69 | 3 |
| 7.2 Profiles of Promising Drugs in the Contraceptive Market | 72 | 1 |
| 7.2.1.1 Overview | 72 | 1 |
| 7.2.1.2 Efficacy | 72 | 1 |
| 7.2.1.3 Safety | 72 | 1 |
| 7.2.1.4 Clinical Study Details | 72 | 1 |
| 7.2.2 Yaz Flex | 72 | 1 |
| 7.2.2.1 Overview | 72 | 1 |
| 7.2.2.2 Efficacy | 72 | 1 |
| 7.2.2.3 Safety | 72 | 1 |
| 7.2.2.4 Clinical Study Details | 72 | 1 |
| 7.2.3 Pill Plus | 73 | 1 |
| 7.2.3.1 Overview | 73 | 1 |
| 7.2.3.2 Efficacy | 73 | 1 |
| 7.2.3.3 Safety | 73 | 1 |
| 7.2.3.4 Clinical Study Details | 73 | 1 |
| 8 Global Contraceptives Market: Competitive Landscape | 74 | 13 |
| 8.1 Evolving competitive landscape | 74 | 1 |
| 8.2 Market Share Analysis | 75 | 1 |
| 8.2.1 Major Players | 76 | 1 |
| 8.3 Competitive Profiling | 77 | 1 |
| 8.3.1 Pfizer | 77 | 1 |
| 8.3.1.1 Company Overview | 77 | 1 |
| 8.3.1.2 Marketed Contraceptive Drugs | 77 | 1 |
| 8.3.1.3 SWOT Analysis | 78 | 1 |
| 8.3.2 Watson | 78 | 1 |
| 8.3.2.1 Company Overview | 78 | 1 |
| 8.3.2.2 Marketed Contraceptive Drugs | 78 | 1 |
| 8.3.2.3 SWOT Analysis | 79 | 1 |
| 8.3.3 Teva Pharmaceuticals | 80 | 1 |
| 8.3.3.1 Company Overview | 80 | 1 |
| 8.3.3.2 Marketed Contraceptive Drugs | 80 | 1 |
| 8.3.3.3 SWOT Analysis | 81 | 1 |
| 8.3.4 Warner Chilcott Ltd. | 81 | 1 |
| 8.3.4.1 Company Overview | 81 | 1 |
| 8.3.4.2 Marketed Contraceptive Drugs | 81 | 1 |
| 8.3.4.3 SWOT Analysis | 82 | 1 |
| 8.3.5 Johnson &Johnson | 83 | 1 |
| 8.3.5.1 Company Overview | 83 | 1 |
| 8.3.5.2 Marketed Contraceptive Drugs | 83 | 1 |
| 8.3.5.3 SWOT Analysis | 84 | 1 |
| 8.3.6 Bayer AG | 84 | 1 |
| 8.3.6.1 Company Overview | 84 | 1 |
| 8.3.6.2 Marketed Contraceptive Drugs | 85 | 1 |
| 8.3.6.3 SWOT Analysis | 85 | 1 |
| 8.3.7 The National Institute of Allergy and Infectious Diseases | 86 | 1 |
| 8.3.7.1 Company Overview | 86 | 1 |
| 8.3.7.2 Marketed Contraceptive Drugs | 86 | 1 |
| 9 Global Contraceptives Market: M&A Landscape | 87 | 6 |
| 9.1 Overview | 87 | 1 |
| 9.1.1 M&A Deals by Value ($) | 87 | 1 |
| 9.1.1.1 Bayer Acquires Schering AG | 88 | 1 |
| 9.1.1.2 Watson Pharmaceuticals Acquires Andrx | 88 | 1 |
| 9.1.1.3 Barr Pharmaceuticals Acquires Rights of Mircette from Organon and Savient | 88 | 1 |
| 9.2 R&D Licensing Agreements | 89 | 1 |
| 9.2.1 Deals by Phase | 89 | 1 |
| 9.2.2 Deals by Geography | 90 | 1 |
| 9.2.3 Phase I | 90 | 1 |
| 9.2.3.1 SOH-075 | 90 | 1 |
| 9.2.4 Phase II | 91 | 1 |
| 9.2.4.1 EMM 310066 | 91 | 1 |
| 9.2.5 Phase III | 91 | 1 |
| 9.2.5.1 WC3026 | 91 | 1 |
| 9.2.6 Marketed Drugs | 92 | 1 |
| 9.2.6.1 Ulipristal Acetate (UPA) | 92 | 1 |
| 10 Global Contraceptives Market: Appendix | 93 | 5 |
| 10.1 Market Definitions | 93 | 1 |
| 10.2 Abbreviations | 93 | 1 |
| 10.3 Research Methodology | 93 | 5 |
| 10.3.1 Coverage | 93 | 1 |
| 10.3.2 Secondary Research | 94 | 1 |
| 10.3.3 Primary Research | 94 | 1 |
| 10.3.4 Forecasts | 94 | 1 |
| 10.3.4.1 Epidemiology-based Forecasting | 95 | 2 |
| 10.3.5 Expert Panel Validation | 97 | 1 |
| 10.4 Contact Us | 97 | 1 |
| 10.5 Disclaimer | 97 | 1 |
| 10.6 Sources | 97 | 1 |